Marianne Hamilton Lopez
Senior Research Director, Biomedical Innovation Duke-Margolis Center for Health Policy
Dr. Marianne Hamilton Lopez is the Senior Research Director of Biomedical Innovation, an adjunct associate professor, and core faculty at the Duke-Margolis Institute for Health Policy in Washington, DC. She leads the strategic design and direction of the Institute’s Biomedical Innovation portfolio, with a focus on medical products development and regulation, real world evidence, infectious disease preparedness, and payment, pricing, and coverage of drugs and medical devices. She also oversees the Value for Medical Products Consortium and partners with Duke University faculty, scholars, and external health experts to advance this work.
Prior to joining Duke-Margolis, Dr. Hamilton Lopez was a senior program officer with the National Academy of Medicine’s Leadership Consortium for a Value & Science-Driven Health System and provided strategic direction and oversight of the Consortium’s Science and Technology portfolio and Clinical Effectiveness Research Innovation and the Digital Learning Collaboratives. She was a Senior Manager at AcademyHealth; a Public Health Community Advisor for the United States Cochrane Center; and the Federal Women’s Program Manager and American Indian/Alaska Native Employment Program Manager for the National Institutes of Health.
Seminars
As next generation gene and cell therapies enter the market, outcomes-based reimbursement is emerging as a critical tool to align pricing with demonstrated clinical benefit. However, manufacturers continue to face significant challenges, from defining meaningful outcome measures to navigating payer expectations and evolving policy frameworks. This workshop offers a focused, strategic deep dive into how innovators can design feasible outcomes-based reimbursement models that build payer confidence and support sustainable patient access.
This workshop will gather experts to discuss:
- Understanding the strategic role of outcomes-based reimbursement in enabling timely access to high-cost advanced therapies
- Strengthening the data foundations and evidence required to engage effectively with payers
- Defining outcomes that are measurable, clinically meaningful, and operationally feasible to track
- Exploring operational challenges related to data collection, durability assessment, and real-world evidence generation
